April 2008
Volume 3, Issue 4
Disease Models
     
Banner

Drug Discovery Today    Latest issue    DDT home    
echoice


RELATED
JOBS


Post Doctoral fellow
Tufts
Massachusetts, USA

Biological Profiling Scientist
Pfizer
Massachusetts, USA

Simulation and Modelling Scientists
Pfizer
Kent, UK

Senior Director
Sanofi-Aventis
New Jersey, USA

Woodcock
The View from Here
Jan Törnell

In this issue of Editor's Choice, I would like to draw your attention to Disease Models. Why would I do that? - You may think that using disease models for drug discovery is pre-historical and belongs in museums...
Read more...

podcasts

Upcoming Issues

May 2008
Translational Drug Discovery

June 2008
Text Mining

July 2008
Systems Biology in Drug Discovery




Editor's Choice

Sign Up for email

Update your details

Unsubscribe

Contact Us


A review of 2006


  Top Reviews
Schizophrenia: Modelling a complex psychiatric disorder

Arguello PA and Gogos JA
Drug Discovery Today: Disease Models

Despite its complexity, schizophrenia can be deconstructed into individual phenotypic components that can be analyzed in animal models. Here we discuss recent advances in genetic animal models, which in conjunction with in vitro and in silico models of disease components promise...

Models of myocardial ischemia

Ytrehus K
Drug Discovery Today: Disease Models

The heart is highly dependent on aerobic metabolism. Given the widespread occurrence of coronary atherosclerosis in the human, myocardial ischemia is a huge clinical problem. Myocardial ischemic is a molecular disease of cardiomyocytes, but also, as a consequence of reduced heart function...

a Models for angiogenesis: From fundamental mechanisms to anticancer treatment research
a
Doumont G, de Visser KE, Derksen PWB and Jonkers J
Drug Discovery Today: Disease Models
a

Angiogenesis, the process of blood vessel formation, constitutes a critical step during embryonic development, cancer progression and metastasis formation. It also constitutes a key target for anticancer therapies. Over the past 20 years different in vitro, ex vivo and in vivo models have been used to understand...


  Abstracts of Key Research Articles

3-D coculture of hepatic sinusoidal cells with primary hepatocytes-design of an organotypical model
Bader A, Knop E, Kern A, Boker K, Fruhauf N, Crome O, Esselmann H, Pape C, Kempka G and Sewing KF
Exp Cell Res. 1996; 226: 223–233

Angiogenesis in transgenic models of multistep carcinogenesis
D'Angelo MG, Afanasieva T and Aguzzi A.
J Neurooncol. 2000; 50: 89–98

Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo
Grant DS, Kinsella JL, Fridman R, Auerbach R, Piasecki BA, Yamada Y, Zain M and Kleinman HK
J Cell Physiol. 1992; 153: 614–625

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes
Hanahan D.
Nature. 1985; 315: 115–122

A systematic look at an old problem
Kirkwood TB
Nature. 2008; 451: 644–647

Applying computational modeling to drug discovery and development
Kumar N, Hendriks BS, Janes KA, de Graaf D and Lauffenburger DA
Drug Discov Today. 2006; 11: 806–811

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P and Westaway D
Nature. 2000; 408: 979–982

C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease
Link CD
Exp Gerontol. 2006; 41: 1007–1013

From the Hodgkin-Huxley axon to the virtual heart
Noble D
J Physiol. 2007; 580: 15–22

Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly-Y M, Gidlof S, Oldfors A, Wibom R, Tornell J, Jacobs HT and Larsson NG
Nature. 2004; 429: 417–423


Data Protection Notice:

This email has been sent to email-address from Elsevier Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, registered in England with registered number 1982084, using Email Reaction’s Technology and Platform.

You are receiving this email because you were a registered user of BioMedNet and requested to receive Gateway Alerts or are a subscriber to Drug Discovery Today. To unsubscribe from this email alert service or sign up for others, click here.

For all inquiries, problems or suggestions regarding this service, please contact DDT@drugdiscoverytoday.com

Copyright © 2007 Elsevier Ltd. All rights reserved. Please read the Elsevier Alerts Privacy Policy and the E-Mail Reaction Privacy Policy.